Results 31 to 40 of about 4,496 (116)

Nucleotide Metabolism in Health and Disease

MedComm, Volume 7, Issue 8, August 2026.
Nucleotide metabolism, including de novo synthesis, salvage pathways, and catabolism, when dysregulated contributes to cancer, immune disorders, metabolic and urological diseases, and radiation injury. Metabolites such as adenosine, cGAMP, NAD, and cAMP and enzymes like RNR are promising therapeutic targets and biomarkers.
Xiaoying Zhao, Yiyu Zeng, Yike Xu, Shu Rao, Mouna Khouchani, Hassna Soummane, Jingyi Li, Rui Liu   +7 more
wiley   +1 more source

Ectonucleotidases CD39 and CD73 expression levels are independent and inverse predictors of survival in muscle‐invasive bladder cancer

The Journal of Pathology: Clinical Research, Volume 12, Issue 4, July 2026.
Abstract Bladder cancer is one of the leading causes of cancer‐related mortality worldwide. Long‐term survival is particularly poor in patients with muscle‐invasive bladder cancer (MIBC). Modulation of purinergic signaling through the ectonucleotidases CD39 and CD73 has emerged as a promising therapeutic strategy in cancer medicine.
Stephan Ledderose, Julia Schwenke, Lennert Eismann, Severin Rodler, Martina Rudelius, Carola Ledderose   +5 more
wiley   +1 more source

Optimization of photobiomodulation therapy for spinal cord injury: A review

Photochemistry and Photobiology, Volume 102, Issue 4, Page 797-831, July/August 2026.
Photobiomodulation (PBM) therapy in the red and near‐infrared range can significantly modulate the secondary injury response and promote the reparative and regenerative potential of neural tissue after spinal cord injury (SCI). At present, due to the nature of delivery methods, the most effective dose and irradiance at the injury site to optimize ...
Isabella K. M. Drew, Alan R. Harvey, Vincent P. Wallace, Stuart I. Hodgetts   +3 more
wiley   +1 more source

Causal Effects of Hydrophilic Bile Acids on Carfilzomib‐Related Cardiovascular Events in Multiple Myeloma: A Mendelian Randomization Study

Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1494-1502, June 2026.
Carfilzomib is highly effective in the treatment of multiple myeloma, but it has been associated with cardiovascular adverse events that impact patient outcomes. Our prior global metabolomic analyses indicated an association between hydrophilic bile acids and carfilzomib‐cardiotoxicity risk, although a causal relationship remained to be determined ...
Samia Shabnaz, Eric Farber‐Eger, Marwa Tantawy, Neyousha Shahisavandi, Timothy J. Garrett, Samuel M. Rubinstein, Michael G. Fradley, Mohammed E. Alomar, Danny DeAvila, Kenneth H Shain, R. Frank Cornell, Daniel Lenihan, Qing Lu, Quinn S Wells, Rachid C. Baz, Yan Gong   +15 more
wiley   +1 more source

Novel Organelle‐Based Intracellular Immunity With Mechanistic and Therapeutic Implications

Barrier Immunity, Volume 2, Issue 2, Page 68-94, June 2026.
A conceptual framework illustrating how PAMPs/DAMPs initiate barrier, innate, adaptive, and intracellular immune responses, with organelle‐based intracellular immunity serving as a central integrator linking metabolism, inflammatory signaling, and therapeutic interventions to restore immune homeostasis.
Keman Xu, Shih‐Yu Hung, Fatma Saaoud, Ying Shao, Yifan Lu, Juanjuan Liu, Bo Yuan, Haiyan Xiang, Hong Wang, Xiaofeng Yang   +9 more
wiley   +1 more source

The Mechanism of NLRP3 Inflammasome Activation and Its Roles in Chronic Rhinosinusitis

World Journal of Otorhinolaryngology - Head and Neck Surgery, Volume 12, Issue 3, Page 362-373, June 2026.
ABSTRACT NLRP3 (NLR family pyrin domain containing 3) is one of the crucial receptors in pathogen recognition receptor (PRR) families which can recognize the pathogen‐associated molecular patterns (PAMPs) and the damage‐associated molecular patterns (DAMPs), thus triggering innate immune response. After NLRP3 activation, it recruits the adaptor protein
Dong‐Lin Li, Yue Li, Yan‐Jie Jiang, Ge‐Hua Zhang, Li‐Hong Chang   +4 more
wiley   +1 more source

The 3‐Hit Metabolic Signaling Model for Autism Spectrum Disorder: A Summary

Autism Research, Volume 19, Issue 5, May 2026.
ABSTRACT Autism spectrum disorder (ASD) is a highly heritable yet environmentally sensitive neurodevelopmental condition whose biological heterogeneity has resisted a unifying causal explanation for over 100 years. The 3‐hit metabolic signaling model proposes that ASD arises from abnormal persistence of an evolutionarily conserved stress‐response ...
Robert K. Naviaux
wiley   +1 more source

Emerging Roles of Adenosine Metabolism in Astrocytes During Brain Injury

CNS Neuroscience &Therapeutics, Volume 32, Issue 5, May 2026.
Adenosine, as a key metabolic and neurotransmitter in the brain, has become an important therapeutic target for improving the efficacy of immunotherapy for stroke. However, gaps in knowledge about its metabolic pathways have become a key factor limiting its clinical translation.
Shu Zhu, Shanshan Zhong, Xiaoru Lin, Chuansheng Zhao, Yugang Li   +4 more
wiley   +1 more source

Chronic Pain: Epidemiology, Pathophysiology, and Clinical Management

MedComm, Volume 7, Issue 5, May 2026.
The multidimensional nature of chronic pain is illustrated through four interconnected domains. (Left) Epidemiology and Global Burden: Chronic pain affects approximately one in five individuals globally, contributing to a rising trend in disability‐adjusted life years (YLDs) and a significant socioeconomic impact.
Zhihao Shang, Zijiao Tian, Zhaoquan Wang, Zerui Yang, Ziyao Wang, Zikang Wang, Ziqing Wang, Xingyuan He, Yu Yan, Yuanfeng Gong, Siyuan Xu, Xinyi Li, Guihua Tian   +12 more
wiley   +1 more source

Small Cell Lung Cancer Establishes a Metabolic Autocrine Mechanism Through Active Extracellular ATP Transport

Cancer Science, Volume 117, Issue 5, Page 1333-1345, May 2026.
Small cell lung cancer (SCLC) actively exports ATP through PANX1 channels, triggering P2RX7‐mediated autocrine signaling and promoting tumor proliferation. Inhibition of PANX1 or P2RX7 disrupts this loop and suppresses tumor growth. ABSTRACT Small cell lung cancer (SCLC) is an aggressive malignancy with a 5‐year survival rate of less than 7%.
Takeshi Tsuruda, Manabu Kodama, Keiichi I. Nakayama   +2 more
wiley   +1 more source